Agilent Technologies Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.9. The key difference: Agilent Technologies Inc pays a 0.69% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals.
| A | PDBC | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | — |
52-Week High | $157.20 | $18.91 |
52-Week Low | $110.24 | $12.90 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
PDBC, an ETF tracking diversified commodities, trades at $17.25, up 0.12% with a bearish technical signal. Recent news highlights institutional inflows, such as Geneos Wealth Management increasing its position by 150.6% in Q1 2026 (Defense World, 2026-07-19), and a Seeking Alpha downgrade to hold due to weakening commodity momentum (2026-06-11). The ETF has outperformed the S&P 500 by nearly 10 percentage points since March 2024 but faces headwinds from oil price declines and geopolitical tensions.
Outlook is mixed: commodities offer inflation hedging potential, with PDBC surging 50% amid supply disruptions (24/7 Wall Street, 2026-05-11), but risks include a potential 'super-squeeze' from Middle East conflicts (HSBC via 24/7 Wall Street, 2026-07-24) and tax-related complexities. Investors should weigh diversification benefits against volatile commodity cycles and roll costs.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →